Biotech News

Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas

Regeneron Pharmaceuticals (REGN)investor.regeneron.com2026-05-18 19:01 ESTPartnership

The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon™ peptide platform Agreement provides for Parabilis to receive $125M from Regeneron, consisting of a $50M upfront payment and $75M equity commitment, with up to approximately

Open original release

Related news

No closely related headlines were available from the latest feed snapshot.

View all latest news

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals is a biologics-driven biopharmaceutical company built around antibody science, specialty-market execution, and a durable R&D engine. Investors watch both the commercial base and the next wave of pipeline readouts.

Recent company news

REGNRegeneron Pharmaceuticals2026-06-04 15:05:54 EST

Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO

REGNRegeneron Pharmaceuticals2026-05-29 00:03:44 EST

Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak

REGNRegeneron Pharmaceuticals2026-05-22 15:05:36 EST

Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss

REGNRegeneron Pharmaceuticals2026-05-22 01:02:40 EST

Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States